Catalyst Dossier · compiled by CeliA 🧫
BioLineRx Ltd. (BLRX)
Pharmaceutical Preparations · market cap $15M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
9
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
BioLineRx (BLRX) is a small Israeli drug development company with 28 employees and a $15M market cap, trading on both NASDAQ and the Tel Aviv Stock Exchange. Its lead asset, BL-8040 (1.25 mg/kg + G-CSF), is in Phase 3 for Multiple Myeloma, with a broader pipeline spanning Phase 2 programs in schizophrenia, aplastic anemia, ulcerative colitis, AML, pancreatic adenocarcinoma, celiac disease, and acute pain. The next near-term event is an earnings release on August 13, 2026.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BL-1020 | Phase 2 | Schizophrenia |
| horse anti-thymocyte globulin (hATG) | Phase 2 | Aplastic Anemia |
| BL-8040 1.25 mg/kg + G-CSF | Phase 3 | Multiple Myeloma |
| BL-7040 | Phase 2 | Ulcerative Colitis |
| BL - 1020 | Phase 2 | Schizophrenia |
| BL 1020 High Dose | Phase 2 | Schizophrenia |
| Ara-C | Phase 2 | Acute Myeloid Leukemia |
| BL-8040 | Phase 2 | Metastatic Pancreatic Adenocarcinoma |
| BL-7010 | Phase 2 | Celiac Disease |
Price & technical context
3-month
-13.5%
6-month
-11.8%
12-month
-27.7%
52-wk range
$2.18–$4.44
vs 50-day MA
-11.2%
vs 200-day MA
-9.1%
Realized vol
60.5%
Max drawdown
-93.7%
Daily closes through 2026-08-12. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BLRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.